PMEF
BCRX icon

Point72 Middle East FZE’s BioCryst Pharmaceuticals BCRX Stock Holding History

Point72 Middle East FZE’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,755
Closed -$89.8K – 1461
2023
Q2 		$89.8K Sell
12,755
-2,300
-15% -$18.5K ﹤0.01% 1221
2023
Q1 		$126K Buy
+15,055
New +$145K ﹤0.01% 1056

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Point72 Middle East FZE's BCRX Position: Q3 2023 in Review

Point72 Middle East FZE sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 12,755 shares — an estimated $89.8K sold.

Point72 Middle East FZE first reported a position in BCRX in Q1 2023 and held it in 2 quarters. The position peaked at $126K in Q1 2023. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • Point72 Middle East FZE reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 12,755 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $89.8K.
  • Point72 Middle East FZE first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's BioCryst Pharmaceuticals position peaked at $126K in Q1 2023.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.